Wall Street Zen Downgrades Bristol Myers Squibb to Buy Rating

Analysts cite concerns over the pharmaceutical company's recent performance.

Apr. 11, 2026 at 5:35am

Got story updates? Submit your updates here. ›

A highly detailed, black-and-white close-up image of complex pharmaceutical manufacturing equipment, conveying the industrial power and technical precision required to produce cutting-edge medicines.An extreme close-up of the intricate mechanics behind Bristol Myers Squibb's drug production facilities reflects the company's focus on innovation and manufacturing excellence.Princeton Today

Investment research firm Wall Street Zen has downgraded its rating on Bristol Myers Squibb (NYSE: BMY) from a 'strong-buy' to a 'buy' recommendation, citing the pharmaceutical company's recent financial results and market performance.

Why it matters

Bristol Myers Squibb is one of the largest pharmaceutical companies in the world, with a diverse portfolio of cancer, immunology, and cardiovascular drugs. The company's stock performance and analyst ratings are closely watched by investors as indicators of its overall health and future growth potential.

The details

In a report issued on Saturday, Wall Street Zen's analysts lowered their rating on Bristol Myers Squibb, noting concerns over the company's recent financial results. Several other research firms have also issued mixed reports on BMY, with some maintaining 'outperform' ratings while others have assigned 'hold' or 'underweight' recommendations.

  • Wall Street Zen issued its downgrade report on Saturday, April 11, 2026.

The players

Wall Street Zen

An investment research firm that provides analysis and ratings on publicly traded companies.

Bristol Myers Squibb

A global biopharmaceutical company focused on developing and delivering medicines for serious diseases, with a strong emphasis on cancer and immune-mediated conditions.

Got photos? Submit your photos here. ›

What they’re saying

“Bristol Myers Squibb's recent financial performance has raised some concerns, leading us to downgrade the stock from a 'strong-buy' to a 'buy' rating.”

— Wall Street Zen Analyst

What’s next

Investors will be closely watching Bristol Myers Squibb's upcoming earnings report and any further analyst commentary on the company's outlook.

The takeaway

The downgrade from Wall Street Zen highlights the ongoing scrutiny and volatility in the pharmaceutical industry, where companies must continually demonstrate strong financial and operational performance to maintain investor confidence.